Pattern of the activator inhibitor in carcinoma and renal diseases.
作者信息
Hedner U, Nilsson I M
出版信息
Scand J Haematol. 1973;11(5):398-404. doi: 10.1111/j.1600-0609.1973.tb00150.x.
Abstract
摘要
相似文献
1
Pattern of the activator inhibitor in carcinoma and renal diseases.
Scand J Haematol. 1973;11(5):398-404. doi: 10.1111/j.1600-0609.1973.tb00150.x.
2
On fibrinolytic split products in serum and urine in uraemia.关于尿毒症患者血清和尿液中的纤维蛋白溶解分裂产物
Scand J Urol Nephrol. 1971;5(3):234-42. doi: 10.3109/00365597109133606.
3
Oestrogenic treatment of prostatic cancer lowers the fibrinolytic activity in vein walls.
Scand J Urol Nephrol. 1974;8(3):169-72. doi: 10.3109/00365597409132124.
4
On coagulation and fibrinolysis in renal failure.关于肾衰竭中的凝血与纤维蛋白溶解
Scand J Haematol Suppl. 1971;15:1-59.
5
Previously undescribed fibrinolysis inhibitor in human blood.人类血液中以前未被描述的纤维蛋白溶解抑制剂。
Nat New Biol. 1971 Dec 8;234(49):180-1. doi: 10.1038/newbio234180a0.
6
Fibrinogen degradation products in serum from patients with cancer.癌症患者血清中的纤维蛋白原降解产物
Acta Chir Scand. 1973;139(6):499-502.
7
The significance of serum creatinine and the blood urea-serum creatinine ratio in azotaemia.
S Afr Med J. 1972 Nov 25;46(47):1828-32.
8
9
Fibrin breakdown products and fibrinolysis in renal disease.肾脏疾病中的纤维蛋白降解产物与纤维蛋白溶解
J Clin Pathol. 1968 Mar;21(2):140-6. doi: 10.1136/jcp.21.2.140.
10
The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy.
Cancer. 1975 Apr;35(4):1223-9. doi: 10.1002/1097-0142(197504)35:4<1223::aid-cncr2820350429>3.0.co;2-t.
Zotero 插件